Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis
HIV-TB Drug Interaction Guideline Development Group
- Chair: Kelly Dooley, MD, PhD, Johns Hopkins University, Baltimore MD USA
- Co-chair: William Burman, MD, Denver Public Health, Denver CO, USA
- Co-chair: Andrew Vernon, MD, MHS, Centers for Disease Control and Prevention, Atlanta GA, USA
Guideline Development Group members:
- Debra Benator, MD, Washington DC Veterans Admin. Medical Center, Washington, DC, USA
- Constance Benson, MD, University of San Diego, San Diego, CA, USA
- David Burger, Pharm D, PhD, Radboud University Medical Center Nijmegen, Nijmegen, The Netherlands
- Mark Cotton, MD PhD, Stellenbosch University, Tygerberg, South Africa
- Jonathan Kaplan, MD, Centers for Disease Control and Prevention, Atlanta, GA, USA
- Gary Maartens, MD, University of Cape Town, Cape Town, South Africa
- Helen McIlleron, MBChB, PhD, University of Cape Town, Cape Town, South Africa
- Jose M. Miro, MD, PhD, Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain
- Lynne Mofenson, MD, NICHD, AIDS Branch, National Institutes of Health, Bethesda, MD, USA
- Alice Pau, Pharm D, NIAID, National Institutes of Health, Bethesda, MD, USA
- Paul Pham, Pharm D, Johns Hopkins University, Baltimore, MD, USA
- Charles Peloquin, Pharm D, University of Florida, Gainesville, FL, USA
- George Siberry, MD, NICHD, AIDS Branch, National Institutes of Health, Bethesda, MD, USA
- Timothy Sterling, MD, Vanderbilt University, Nashville, TN, USA
- Kimberly Struble, Pharm D, Center for Drug Evaluation & Research, Food and Drug Administration, Rockville MD, USA
- Montserrat Tuset, Pharm D, PhD, Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain
- Heather Watts, MD, NICHD, AIDS Branch, National Institutes of Health, Bethesda, MD, USA
- Paul Weidle, Pharm D, MPH, Centers for Disease Control and Prevention, Atlanta, GA, USA
- Marc Weiner, MD, Audie L. Murphy Veterans Admin. Medical Center, San Antonio TX, USA
Members of the writing group were asked if they served as employees, if they served on a paid advisory board, if they owned stock, if they received grants, or if they received speaker fees from companies whose products were reviewed. The following competing interests were reported:
| NAME | Employee | Paid advisory board | Own stock | Received grant(s) | Speaker fees |
| Benator |
N |
N |
N |
N |
N |
| Benson |
N |
N |
N |
N |
N |
| Burger |
N |
Y |
N |
Y |
N |
| Burman |
N |
Y (DSMB) |
N |
N |
N |
| Cotton |
N |
N |
N |
Y (2) |
Y (in 2010) |
| Dooley |
N |
N |
N |
Y |
N |
| Kaplan |
N |
N |
N |
N |
N |
| Maartens |
N |
N |
N |
N |
N |
| McIlleron |
N |
N |
N |
N |
N |
| Miro |
N |
Y |
N |
Y |
Y |
| Mofenson |
N |
N |
N |
N |
N |
| Pau |
N |
N |
N |
N |
N |
| Peloquin |
N |
N |
N |
Y (Indirect) |
N |
| Pham |
N |
Y |
N |
N |
N |
| Siberry |
N |
N |
N |
N |
N |
| Sterling |
N |
N |
N |
Y (thru Univ.) |
N |
| Struble |
N |
N |
N |
N |
N |
| Tuset |
N |
N |
N |
Y |
Y |
| Watts |
N |
N |
N |
N |
N |
| Weidle |
N |
N |
N |
N |
N |
| Weiner |
N |
N |
N |
Y |
N |
N=No competing interest
Y=Yes, possible competing interest as noted
Page last reviewed: December 9, 2013